Logo

TSHA

Taysha Gene Therapies, Inc.

TSHA

Taysha Gene Therapies, Inc. • NASDAQ
$4.74 ▼ -2.47% (-0.12)
Market Cap $1.24 B
52w High $5.51
52w Low $1.05
Dividend Yield 0%
P/E -14.36
Volume 754.35K
Outstanding Shares 300.48M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $33.738M ▲ $-32.733M ▼ 0% ▲ $-0.093 ▼ $-32.432M ▼
Q2-2025 $1.986M ▼ $28.739M ▲ $-26.882M ▼ -1.354K% ▼ $-0.09 ▼ $-26.588M ▼
Q1-2025 $2.302M ▲ $23.723M ▲ $-21.529M ▼ -935.23% ▼ $-0.08 ▲ $-21.227M ▼
Q4-2024 $2.022M ▲ $21.954M ▼ $-18.785M ▲ -929.031% ▲ $-0.092 ▲ $-18.459M ▲
Q3-2024 $1.788M $27.686M $-25.524M -1.428K% $-0.095 $-25.206M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $297.344M ▼ $316.554M ▼ $97.565M ▲ $218.989M ▼
Q2-2025 $312.761M ▲ $333.331M ▲ $84.604M ▲ $248.727M ▲
Q1-2025 $116.593M ▼ $138.362M ▼ $83.303M ▼ $55.059M ▼
Q4-2024 $139.036M ▼ $160.364M ▼ $88.839M ▼ $71.525M ▼
Q3-2024 $157.688M $180.217M $91.42M $88.797M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-32.733M ▼ $-24.166M ▼ $-48K ▼ $8.797M ▼ $-15.417M ▼ $-24.274M ▼
Q2-2025 $-26.882M ▼ $-20.182M ▲ $62K ▲ $216.288M ▲ $196.168M ▲ $-20.184M ▲
Q1-2025 $-21.529M ▼ $-22.02M ▼ $-371K ▼ $-52K ▲ $-22.443M ▼ $-22.398M ▼
Q4-2024 $-18.785M ▲ $-18.308M ▲ $13K ▲ $-357K ▼ $-18.652M ▼ $-18.306M ▲
Q3-2024 $-25.524M $-21.615M $-35K $6.595M $-15.055M $-21.65M

Five-Year Company Overview

Income Statement

Income Statement Taysha still looks like a classic clinical‑stage biotech: essentially no product revenue and ongoing, meaningful losses. The good news is that the size of the losses has been easing over the last couple of years, suggesting tighter cost control and a more focused R&D strategy. Earnings per share remain clearly negative, but the direction has been improving as the company has narrowed its pipeline and concentrated spending on its lead program.

Balance Sheet

Balance Sheet The balance sheet is small and very cash‑heavy, which is typical for a young biotech without approved products. Cash makes up most of total assets, with a modest amount of debt in place. Shareholders’ equity dipped earlier in the period but has since been rebuilt, though the capital base is still thin. Overall, the company has some financial flexibility today, but its size and dependence on cash reserves highlight sensitivity to future funding conditions and clinical outcomes.

Cash Flow

Cash Flow Cash flows reflect a company that is still firmly in investment mode. Operating cash burn has been steady but has improved somewhat as spending has become more disciplined. Free cash flow is consistently negative, which is expected for a firm funding clinical trials without commercial revenue yet. Capital spending is very light; the main cash use is R&D and operating costs, not big facilities or equipment. Long term, continued progress will likely depend on a mix of existing cash, potential partnerships, and future capital raises.

Competitive Edge

Competitive Edge Taysha’s competitive position rests on a narrow but potentially powerful niche: gene therapies for rare central nervous system diseases. Its proprietary miRARE platform is designed to finely control gene expression, which addresses a key safety challenge in gene therapy and could be a real differentiator if it continues to work as intended in humans. The company also benefits from a strong academic collaboration and past strategic backing from a large pharma partner, which add credibility. On the other hand, it is highly concentrated in one lead asset for Rett syndrome and operates in a crowded, fast‑moving gene therapy field where scientific, regulatory, and manufacturing hurdles are all high.

Innovation and R&D

Innovation and R&D Innovation is the core of Taysha’s story. The miRARE platform and the lead program TSHA‑102 for Rett syndrome are designed to tackle a tough neurological disease at its genetic root, while trying to avoid the harm of over‑correcting the gene. Early clinical data and multiple expedited regulatory designations suggest regulators see meaningful potential here. The company has deliberately narrowed its pipeline to focus money and talent on this single lead program, which can speed progress but also increases dependence on one main shot on goal. Future value will hinge on ongoing trial results, safety over time, and the ability to translate this platform into additional indications later on.

Summary

Overall, Taysha is a small, high‑risk, high‑reward biotech that is still in the development phase, with minimal revenue and ongoing cash burn. Financially, the trend in losses and cash use is improving but the business remains fully dependent on external capital and eventual clinical success. Strategically, the company has a focused and differentiated technology platform, strong scientific partners, and a clear path centered on Rett syndrome. The main opportunities are successful approval and commercialization of TSHA‑102 and potential expansion of the platform; the main risks are scientific or regulatory setbacks, funding needs over time, and heavy reliance on a single lead program. This is best viewed as a long‑duration R&D story rather than a traditional earnings‑driven business at this stage.

NEWS

November 4, 2025 · 7:00 AM UTC

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

October 28, 2025 · 8:00 AM UTC

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Read more

October 16, 2025 · 4:01 PM UTC

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Read more

October 9, 2025 · 8:00 AM UTC

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Read more

October 3, 2025 · 4:05 PM UTC

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more